(Q36869456)

16 August 2017

1 reference

title

Interleukins. Clinical pharmacokinetics and practical implications (English)

1 reference

16 August 2017

1 reference

Bocci V

1

1 reference

16 August 2017

publication date

1 October 1991

1 reference

Clinical Pharmacokinetics

16 August 2017

published in

1 reference

16 August 2017

volume

21

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

274-284

1 reference

A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects

16 August 2017

cites work

1 reference

12 December 2020

Antitumor activity of recombinant interleukin 6 in mice

1 reference

12 December 2020

Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

1 reference

12 December 2020

The consequences of excess levels of haemopoietic growth factors

1 reference

12 December 2020

Clearance and tissue distribution of recombinant human interleukin 1 beta in rats

1 reference

12 December 2020

Phase I study of recombinant tumor necrosis factor in cancer patients.

1 reference

12 December 2020

Tissue localization and fate in mice of injected multipotential colony-stimulating factor

1 reference

12 December 2020

Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice

1 reference

12 December 2020

Toxic effects of recombinant tumor necrosis factor in suckling mice. Comparisons with interferon alpha/beta

1 reference

12 December 2020

Central nervous system toxicity of interferons and other cytokines

1 reference

12 December 2020

What roles have anti-interferon antibodies in physiology and pathology?

1 reference

12 December 2020

Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat.

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo

1 reference

12 December 2020

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

1 reference

12 December 2020

The distribution and clearance of radiolabeled human interleukin-1 beta in mice

1 reference

12 December 2020

Metabolism of protein anticancer agents.

1 reference

12 December 2020

Renal Metabolism of Rabbit Serum Interferon

1 reference

12 December 2020

Interleukin 1 activity in normal human urine

1 reference

12 December 2020

New methods of drug delivery

1 reference

12 December 2020

Catabolic sites of human interferon-gamma

1 reference

12 December 2020

Interactions between cytokines and α2-macroglobulin

1 reference

12 December 2020

Identification of alpha 2-macroglobulin as a carrier protein for IL-6

1 reference

12 December 2020

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

1 reference

12 December 2020

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

1 reference

12 December 2020

Purification and biochemical characterization of a soluble human interferon gamma receptor expressed in Escherichia coli.

1 reference

12 December 2020

Structures of the major carbohydrates of natural human interleukin-2.

1 reference

12 December 2020

Is interferon effective after oral administration? The state of the art

1 reference

12 December 2020

Sites of clearance of leucocyte pyrogen in the rabbit

1 reference

12 December 2020

Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.

1 reference

12 December 2020

Systemic administration of recombinant human interleukin-2 in mice

1 reference

12 December 2020

Passage of immunomodulators across the blood-brain barrier.

1 reference

12 December 2020

Studies on tumor necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNF

1 reference

12 December 2020

Soluble cytokine receptors are present in normal human urine

1 reference

12 December 2020

Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo

1 reference

12 December 2020

Transcytosis of albumin in capillary endothelium

1 reference

12 December 2020

Structure of tumour necrosis factor

1 reference

12 December 2020

Serum inhibitors of interleukin-2.

1 reference

12 December 2020

Somnogenic cytokines and models concerning their effects on sleep

1 reference

12 December 2020

Administration of interferon at night may increase its therapeutic index

1 reference

12 December 2020

Pulmonary catabolism of interferons: alveolar absorption of 125I-labeled human interferon alpha is accompanied by partial loss of biological activity

1 reference

12 December 2020

The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Rate of clearance of circulating leukocytic endogenous mediator in the rat

1 reference

12 December 2020

Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone.

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.

1 reference

12 December 2020

Carbohydrate-Specific Receptors of the Liver

1 reference

12 December 2020

Drug delivery systems and routes of administration of peptide and protein drugs

1 reference

12 December 2020

Studies on tumor necrosis factor (TNF). III. Plasma disappearance curves after intramuscular, subcutaneous, intraperitoneal, and oral administration of human recombinant TNF

1 reference

12 December 2020

Immunomodulators as local hormones: new insights regarding their clinical utilization

1 reference

12 December 2020

Autoantibodies to cytokines--friends or foes?

1 reference

12 December 2020

Phase I clinical trial of recombinant human tumor necrosis factor

1 reference

12 December 2020

An inhibitor of interferon action: I. Physical association of the inhibitor with interferon-gamma

1 reference

12 December 2020

Sarcolectin: an interferon antagonist extracted from hamster sarcomas and normal muscles. Isolation, characterization, and purification

1 reference

12 December 2020

Phase I study of recombinant human tumor necrosis factor

1 reference

12 December 2020

Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines

1 reference

12 December 2020

A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

1 reference

12 December 2020

Interleukin-6: possible implications in human diseases

1 reference

12 December 2020

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

1 reference

12 December 2020

Native interleukin 1 inhibitors

1 reference

12 December 2020

Roles of interferon produced in physiological conditions. A speculative review

1 reference

12 December 2020

Systemic administration of interleukin-2 in humans

1 reference

12 December 2020

Pharmacokinetics of murine tumor necrosis factor

1 reference

12 December 2020

Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease

1 reference

12 December 2020

Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy

1 reference

12 December 2020

Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor

1 reference

12 December 2020

Fate and biological action of human recombinant interleukin 1β in the ratin vivo

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.

1 reference

12 December 2020

Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth

1 reference

12 December 2020

Neuromodulative actions of cytokines

1 reference

12 December 2020

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Hypothalamic neuronal responses to cytokines

1 reference

12 December 2020

Interleukin-2-induced lung permeability is mediated by leukotriene B4.

1 reference

12 December 2020

Identification of alpha 2-macroglobulin as a cytokine binding plasma protein. Binding of interleukin-1 beta to "F" alpha 2-macroglobulin

1 reference

12 December 2020

Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat

1 reference

12 December 2020

The kidney is the main site of interferon catabolism

1 reference

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

12 December 2020

Drug therapy. Clinical Pharmacokinetics (first of two parts).

1 reference

12 December 2020

Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice

1 reference

12 December 2020

Clearance of interleukin 2 from the blood of normal and T cell-depleted mice

1 reference

12 December 2020

Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

1 reference

12 December 2020

Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor

1 reference

12 December 2020

Distribution of interferon in body fluids and tissues

1 reference

12 December 2020

Evaluation of routes of administration of interferon in cancer: a review and a proposal

1 reference

12 December 2020

A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.

1 reference

12 December 2020

Rate of clearance of interleukin-1 from the blood of normal and nephrectomized rats

1 reference

12 December 2020

Studies on tumor necrosis factor (TNF)—I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration

1 reference

12 December 2020

10.2165/00003088-199121040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1047086385

0 references

1 reference